Abstract 69P
Background
Colorectal cancer is one of the commonest malignancies worldwide. Next Generation Sequencing (NGS) helps inform treatment pathways for patients post surgery, and also provides valuable information regarding genetic mutations in cancer, the pathogenesis and biology of the disease. We reviewed NGS mutation profiling in our colorectal cancer patients.
Methods
NGS analysis was performed over a 7 year period. Data retrieved from medical records and pathology reports.
Results
92 patients underwent surgery for colorectal cancer during the study period. Mean age: 71 years (Range:44-87). M:F: 1.05:1 43 patients (46.7%) were found to have mutations on NGS sequencing. No significant difference in age, sex, tumour size, lymph node ratio or stage at presentation between the two groups. NGS mutation was significantly associated with right sided disease (p=0.01, Fishers exact test), and this association was highly significant for the BRAF V600e mutation (p=0.0001), NGS mutation was significantly associated with mucinous disease (p=0.04), lymphovascular and / or perineural invasion (p=0.02), and microsatellite instability (p=0.0136), but not metastatic disease at presentation (p=1). Kaplan Meier survival analysis revealed no difference in survival between patients with NGS mutations and those without (p=0.52) or on any subset analysis. COX proportional hazards testing revealed only a significant relationship between tumour size and survival in all patients on multivariate analysis (p=0.002).
Conclusions
NGS sequencing provides relevant information regarding the association of cancers with aggressive features and microsatellite instability. Association of the BRAF mutation with right sided colon cancers has been described previously and may reflect a different pathway to carcinogenesis in the right colon, which has been postulated to have a different origin to the left colon. Significant association of gene mutations with microsatellite instability, but no difference in metastatic disease and overall survival may relect better immune response to these tumours, MSI has been observed to be associated with reduced risk of metastasis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Comprehensive analysis of clinical characteristics and germline status among colorectal cancer patients in a tertiary care center in Thailand
Presenter: NUTDANAI ROILA
Session: Cocktail & Poster Display session
Resources:
Abstract